These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18201816)

  • 1. Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues.
    McLeod DG
    Eur Urol; 2008 May; 53(5):898-9. PubMed ID: 18201816
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues.
    Bamias A; Dimopoulos MA
    Eur Urol; 2008 May; 53(5):899-900. PubMed ID: 18201817
    [No Abstract]   [Full Text] [Related]  

  • 3. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A; Schally AV; Djavan B
    Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory prostate cancer with somatostatin analogues and glucocorticoids.
    Trafalis DT; Athanassiou AE
    J BUON; 2008; 13(2):295-6. PubMed ID: 18555482
    [No Abstract]   [Full Text] [Related]  

  • 5. New approaches to the therapy of various tumors based on peptide analogues.
    Schally AV
    Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Adolfsson J
    Eur Urol; 2009 May; 55(5):1074. PubMed ID: 19200637
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Orvieto M; Eggener S
    Eur Urol; 2009 May; 55(5):1073-4. PubMed ID: 19200640
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer.
    Whelan P
    Eur Urol; 2008 Oct; 54(4):815. PubMed ID: 18538468
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer.
    Bastian PJ
    Eur Urol; 2008 Oct; 54(4):814. PubMed ID: 18538467
    [No Abstract]   [Full Text] [Related]  

  • 10. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
    Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
    Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    Whelan P
    Eur Urol; 2008 Oct; 54(4):823-4. PubMed ID: 18243509
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Stanislaus P; Seitz M
    Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy. what can they teach us?
    Scattoni V
    Eur Urol; 2009 Apr; 55(4):910. PubMed ID: 18485582
    [No Abstract]   [Full Text] [Related]  

  • 14. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
    Lee LT; Schally AV; Liebow C; Lee PP; Lee PH; Lee MT
    Anticancer Res; 2008; 28(5A):2599-605. PubMed ID: 19035284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study.
    Albrecht W
    Eur Urol; 2008 Aug; 54(2):390-1. PubMed ID: 18339476
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Sciarra A
    Eur Urol; 2009 Feb; 55(2):320-1. PubMed ID: 18838210
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Tombal B
    Eur Urol; 2009 Feb; 55(2):321. PubMed ID: 18838209
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.
    de la Rosette JJ
    Eur Urol; 2009 Mar; 55(3):647-8. PubMed ID: 18508190
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.
    Cestari A; Guazzoni G
    Eur Urol; 2009 Mar; 55(3):648-9. PubMed ID: 18508189
    [No Abstract]   [Full Text] [Related]  

  • 20. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J; Altwein JE
    Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.